Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,631

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

December 31, 2010

Conditions
Meningococcal Disease
Interventions
BIOLOGICAL

rMenB+OMV NZ

BIOLOGICAL

Placebo

Trial Locations (10)

Unknown

Site 13: Liceo Diego Aracena de Lo Barnechea, Monseñor Escrivá de Balaguer 14630, Lo Barnechea

Site 41: Colegio Antonio Hermida Fabres, Av. Coronel Alejandro Sepúlveda N° 6801

Site 43: Liceo José Victorino Lastarria, Av. Miguel Claro N° 32

Site 51: Centro Para vacunas en Desarrollo. Hospital de Niños Roberto del Rio, Av. Prof Zañartu 1085

Site 15: Liceo Carmela Carvajal de Prat, Avda. Italia 980

Site 14: Colegio Parroquial Santa Rosa de Lo Barnechea, Avda. Raúl Labbé Nº 13.799

Site 42: Centro Educacional Eduardo de la Barra, Calle A, N° 6301

Site 61: Facultad de Medicina. Universidad de Valparaíso., Hontaneda # 2653. Valparaíso

Site 11: Complejo Educacional Eduardo Cuevas Valdés, Lo Barnechea

Site 12: Colegio San Jose de Lo Barnechea, Santiago

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY